NAS:ENTA (USA)
Business Description
Enanta Pharmaceuticals Inc
NAICS : 325412
SIC : 2835
500 Arsenal Street, Watertown, MA, USA, 02472
Compare
Compare
Traded in other countries / regions
9EP.Germany
•
ENTA.USA
Description
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 15.46 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -0.14 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 18.39 | |||||
| Beneish M-Score | -1.31 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -21.6 | |||||
| 3-Year Book Growth Rate | -0.9 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 95.99 | |||||
| 9-Day RSI | 89.25 | |||||
| 14-Day RSI | 82.95 | |||||
| 6-1 Month Momentum % | -13.76 | |||||
| 12-1 Month Momentum % | 17.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 11.12 | |||||
| Quick Ratio | 11.12 | |||||
| Cash Ratio | 9.12 | |||||
| Days Sales Outstanding | 89.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.4 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -143.98 | |||||
| Net Margin % | -122.68 | |||||
| ROE % | -28.13 | |||||
| ROA % | -25.48 | |||||
| ROIC % | -87.38 | |||||
| ROC (Joel Greenblatt) % | -470.52 | |||||
| ROCE % | -32.24 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 15.25 | |||||
| PB Ratio | 3.94 | |||||
| Price-to-Tangible-Book | 3.99 | |||||
| EV-to-EBIT | -8.81 | |||||
| EV-to-EBITDA | -9.02 | |||||
| EV-to-Revenue | 12.66 | |||||
| EV-to-Forward-Revenue | 5.91 | |||||
| EV-to-FCF | -13.33 | |||||
| Price-to-Projected-FCF | 4.01 | |||||
| Price-to-Net-Current-Asset-Value | 4.86 | |||||
| Price-to-Net-Cash | 6.14 | |||||
| Earnings Yield (Greenblatt) % | -11.37 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:ENTA
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 91.563 | ||
| EPS (TTM) ($) | -5.52 | ||
| Beta | 0.41 | ||
| Volatility % | 85.65 | ||
| 14-Day RSI | 82.95 | ||
| 14-Day ATR ($) | 3.885349 | ||
| 20-Day SMA ($) | 55.089 | ||
| 12-1 Month Momentum % | 17.64 | ||
| 52-Week Range ($) | 37.59 - 102 | ||
| Shares Outstanding (Mil) | 20.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Enanta Pharmaceuticals Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||